(Q39730584)

English

In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates

scientific article published on January 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 September 2017

In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates (English)

1 reference

Europe PubMed Central

14 September 2017

gram-positive bacteria

0 references

0 references

1 reference

based on heuristic

inferred from title

Ellie J. C. Goldstein

1

object named as

Ellie J C Goldstein

1 reference

Europe PubMed Central

14 September 2017

Diane M. Citron

2

object named as

Diane M Citron

1 reference

Europe PubMed Central

14 September 2017

C. Vreni Merriam

3

object named as

C Vreni Merriam

1 reference

Europe PubMed Central

14 September 2017

4

object named as

Yumi A Warren

1 reference

Europe PubMed Central

14 September 2017

author name string

Kerrin L Tyrrell

5

1 reference

Europe PubMed Central

14 September 2017

Helen T Fernandez

6

1 reference

Europe PubMed Central

14 September 2017

language of work or name

0 references

publication date

1 January 2003

1 reference

Europe PubMed Central

14 September 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

14 September 2017

47

1 reference

Europe PubMed Central

14 September 2017

1

1 reference

Europe PubMed Central

14 September 2017

337-341

1 reference

Europe PubMed Central

14 September 2017

In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=148963

14 September 2017

Resistance studies with daptomycin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=148963

14 September 2017

Development of daptomycin for gram-positive infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=148963

14 September 2017

Identification and antimicrobial resistance patterns of clinical isolates of Clostridium clostridioforme, Clostridium innocuum, and Clostridium ramosum compared with those of clinical isolates of Clostridium perfringens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=148963

14 September 2017

Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=148963

14 September 2017

Effect of calcium on in vitro activity of LY146032 against Clostridium difficile

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=148963

14 September 2017

In vitro activities of daptomycin (LY146032) and paldimycin (U-70,138F) against anaerobic gram-positive bacteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=148963

14 September 2017

Effects of reduced cation supplement recommendations (National Committee for Clinical Laboratory Standards) on daptomycin antistaphylococcal activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=148963

14 September 2017

Daptomycin disrupts membrane potential in growing Staphylococcus aureus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=148963

14 September 2017

Recommendations for preventing the spread of vancomycin resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=148963

14 September 2017

In vitro activity of a new cyclic lipopeptide antibiotic, LY146032, against gram-positive clinical bacteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=148963

14 September 2017

In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=148963

14 September 2017

Treatment of Clostridium difficile colitis in hamsters with a lipopeptide antibiotic, LY146032.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=148963

14 September 2017

Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=148963

17 June 2018

In vitro activity of LY146032 against gram-positive bacteria.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=148963

17 June 2018

In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococi, enterococci and Clostridium difficile

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=148963

17 June 2018

Reduced susceptibility of Clostridium difficile to metronidazole.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=148963

20 August 2018

Susceptibility of Clostridium difficile to LY146032

1 reference

https://pubmed.ncbi.nlm.nih.gov/12499210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative activity of LY146032 against anaerobic cocci

1 reference

https://pubmed.ncbi.nlm.nih.gov/12499210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

LY146032 treatment of Clostridium difficile colitis in hamsters

1 reference

https://pubmed.ncbi.nlm.nih.gov/12499210

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.47.1.337-341.2003

1 reference

Europe PubMed Central

14 September 2017

1 reference

Europe PubMed Central

14 September 2017

1 reference

Europe PubMed Central

14 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39730584&oldid=2089186883"